Summit Trail Advisors, LLC Caladrius Biosciences, Inc. Transaction History

Summit Trail Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	BUY	$1.6 - $3.0 $28,368 - $53,190	17,730 New	17,730 $27,000
Q3 2020 Nov 16, 2020	SELL	$1.6 - $3.0 $28,368 - $53,190	-17,730 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.21 - $3.47 $21,453 - $61,523	17,730 New	17,730 $32,000
Q4 2019 Feb 13, 2020	SELL	$2.02 - $2.85 $35,814 - $50,530	-17,730 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$2.22 - $2.99 $39,360 - $53,012	17,730 New	17,730 $46,000
Q2 2019 Aug 08, 2019	SELL	$2.25 - $3.6 $39,892 - $63,828	-17,730 Closed	0 $0
Q1 2019 May 16, 2019	BUY	$3.48 - $5.32 $61,700 - $94,323	17,730 New	17,730 $64,000
Q2 2018 Aug 10, 2018	SELL	$3.8 - $8.64 $67,374 - $153,187	-17,730 Closed	0 $0
Q1 2018 May 22, 2018	SELL	$3.7 - $6.09 $202,708 - $333,646	-54,786 Reduced 75.55%	17,730 $73,000
Q1 2018 May 21, 2018	BUY	$3.7 - $6.09 $202,708 - $333,646	54,786 Added 309.0%	72,516 $73,000
Q4 2017 Feb 14, 2018	BUY	$2.66 - $3.71 $47,161 - $65,778	17,730	17,730 $76,000

Ticker CLBS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,583,200
Market Cap $25.8M
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...

Get notified when there are updates to the investment portfolio of Summit Trail Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Summit Trail Advisors, LLC with notifications on news.